BioCryst Pharmaceuticals
BCRX
BCRX
234 hedge funds and large institutions have $1.87B invested in BioCryst Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 76 increasing their positions, 59 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
6% more funds holding
Funds holding: 221 → 234 (+13)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
1.9% less ownership
Funds ownership: 81.83% → 79.93% (-1.9%)
Holders
234
Holding in Top 10
6
Calls
$54.3M
Puts
$18M
Top Buyers
| 1 | +$32.1M | |
| 2 | +$17.9M | |
| 3 | +$9.94M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.54M |
| 5 |
D.E. Shaw & Co
New York
|
+$6.24M |
Top Sellers
| 1 | -$43.7M | |
| 2 | -$20.2M | |
| 3 | -$15.5M | |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$13.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.7M |